Design of a recombinant immunotoxin against the human granulocyte-colony stimulating factor receptor

  • E. Babavalian
  • M. ZeinoddiniEmail author
  • A. R. Saeedinia
  • R. Mohammadi
  • N. Xodadadi
Original Article


Immunotoxin is a new strategy for protein therapy of cancer. This engineered protein contains two parts, the immune part which is an antibody or cytokine, directed against the cancer cell receptor, and the toxin part consisting of a plant or bacterial toxin leading to apoptosis by protein synthesis inhibition. The knowledge of cell-surface receptor overexpression in cancer cells can help scientists to construct new anti-cancer agents. The granulocyte colony stimulating factor (G-CSF) receptor is expressed on the cell surface of some blood cancers such as acute myeloid leukemia (AML). Therefore, this receptor can be used as an immunotoxin for treatment of some cancers. The aim of this work was to design and produce DT-GCSF immunotoxin using truncated DT fused to G-CSF. For fusion protein construction, DT389 and G-CSF fragments, were amplified by PCR using specific primers. A flexible linker SerGly4SerMet (SG4SM) was used to fuse the PCR products by SOEing PCR procedure to achieve an appropriate fusion protein, and the fused fragment was subcloned into pET21b. The new construction (pET-DT389GCSF) was transformed into E. coli strain BL21 (DE3) and the expression of the construction was confirmed by SDS-PAGE and Western blotting techniques. The data demonstrated the expression and purity rates of DT389GCSF about 25% and 90%, respectively. This chimeric protein construction can be used as a new anti-AML drug, but its in vitro and in vivo biological activity should be analyzed.


Diphtheria toxin Immunotoxin Granulocyte colony-stimulating factor Expression Purification 



We would like to thank the Department of Bioscience and Biotechnology, Malek-Ashtar University of Technology for financial support of this project.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Inform consent

Research was not involved in the human participants and/or animals.


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefGoogle Scholar
  2. 2.
    Narang AS, Desai DS (2009) Anticancer drug development: unique aspects of pharmaceutical development. In: Pharmaceutical perspectives of cancer therapeutics. Springer, New York, pp 49–92CrossRefGoogle Scholar
  3. 3.
    Saijo N, Tamura T, Nishio K (2003) Strategy for the development of novel anticancer drugs. Cancer Chemother Pharmacol 52(Suppl 1):S97–S101CrossRefGoogle Scholar
  4. 4.
    Wu HC, Chang DK, Huang CT (2006) Targeted therapy of cancer. J Cancer Mol 2(2):57–66Google Scholar
  5. 5.
    Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nature Rev Cancer 6:559–565CrossRefGoogle Scholar
  6. 6.
    Kreitman RJ (2006) Immunotoxins for targeted cancer therapy. AAPS J 8:532–551CrossRefGoogle Scholar
  7. 7.
    Kawakami K, Aggarwal BB, Puri RK (2004) Cytotoxins and immunotoxins for cancer therapy: clinical applications. CRC Press, Boca RatonCrossRefGoogle Scholar
  8. 8.
    Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers (Basel) 6(3):1769–1792CrossRefGoogle Scholar
  9. 9.
    Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer 4(10):806–813CrossRefGoogle Scholar
  10. 10.
    Sagar J, Chaib B, Sales K, Winslet M, Seifalian A (2007) Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int 7:9CrossRefGoogle Scholar
  11. 11.
    Reiter Y (2001)) Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 124:81–93Google Scholar
  12. 12.
    Akbari B, Farajnia S, Ahdi Khosroshahi S, Safari F, Yousefi M, Dariushnejad H et al (2017) Immunotoxins in cancer therapy: review and update. Int Rev Immunol 36(4):207–219CrossRefGoogle Scholar
  13. 13.
    Pastan I, Pai LH, Brinkmann U, FitzGerald D (1996) Recombinant immunotoxins. Breast Cancer Res Treat 38:3–9CrossRefGoogle Scholar
  14. 14.
    Kreitman RJ (2009) Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23(1):1–13CrossRefGoogle Scholar
  15. 15.
    Allahyari H, Heidari S, Ghamgosha M, Saffarian P, Amani J (2017) Immunotoxin: a new tool for cancer therapy. Tumour Biol. CrossRefPubMedGoogle Scholar
  16. 16.
    Antignani A, Fitzgerald D (2013) Immunotoxins: the role of the toxin. Toxins (Basel) 5(8):1486–1502CrossRefGoogle Scholar
  17. 17.
    Potala S, Sahoo SK, Verma RS (2008) Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. Drug Discov Today 13(17–18):807–815CrossRefGoogle Scholar
  18. 18.
    Amraei M, Zeinoddini M, Solimani M, Saeedinia AR (2015) Cloning, expression, purification and toxicity assessment of diphtheria toxin-interleukin2 fusion protein. Iran J Pol Med 4(2):105–113Google Scholar
  19. 19.
    Fallah MJ, Akbari B, Saeedinia AR, Karimi M, Vaez M, Zeinoddini M et al (2003) Overexpression of recombinant human granulocyte colony stimulating factor in E.coli. Iran J Med Sci 28(3):131–134Google Scholar
  20. 20.
    Srivastava S, Luqman S (2015) Immune-o-toxins as the magic bullet for therapeutic purposes. Biomed Res Ther 2(1):169–183CrossRefGoogle Scholar
  21. 21.
    Vitetta ES, Thorpe PE, Uhr JW (1993) Immunotoxins: magic bullets or misguided missiles? Immunol Today 14(6):252–259CrossRefGoogle Scholar
  22. 22.
    Strebhardt K, Ullrich A (2008) Paul Ehrlich,s magic bullet concept: 100 yeats of progress. Nat Rev Cancer 8(6):473–480CrossRefGoogle Scholar
  23. 23.
    Collier RJ (2001) Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century. Toxicon 39(11):1793–1803CrossRefGoogle Scholar
  24. 24.
    Kawakami K, Nakajima O, Morishita R, Nagai R (2006) Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. Sci World J 6:781–790CrossRefGoogle Scholar
  25. 25.
    Manoukian G, Hagemeister F (2009) Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 9(11):1445–1451.CrossRefGoogle Scholar
  26. 26.
    Figgitt DP, Lamb HM, Goa KL (2000) Denileukin diftitox. Am J Clin Dermatol 1(1):67–72CrossRefGoogle Scholar
  27. 27.
    Eklund JW, Kuzel TM (2005) Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther 5(1):33–38.CrossRefGoogle Scholar
  28. 28.
    Kreitman RJ, Pastan I (1997) Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood 90:252–259PubMedGoogle Scholar
  29. 29.
    Chadwick DE, Williams DP, Niho Y, Murphy JR, Minden MD (1993) Cytotoxicity of a recombinant diphtheria toxin-granulocyte colony-stimulating factor fusion protein on human leukemic blast cells. Leuk Lymphoma 11(3–4):249–262CrossRefGoogle Scholar
  30. 30.
    Siahmazgi MG, Khalili MAN, Ahmadpour F, Khodadadi S, Zeinoddini M (2018) In silico design of fusion toxin DT389GCSF and comparison of interaction it with GCSF receptor rather than DT486GCSF. Curr Comput Aided Drug Des. CrossRefPubMedGoogle Scholar
  31. 31.
    Moghaddas M, Zeinoddini M, Saeedinia AR, Bayat S (2018) Structural and functional assessment of diphtheria fusion toxin: DT389GCSF. J Bionanosci 12(2):240–244CrossRefGoogle Scholar
  32. 32.
    Lee JW, Nakamura LT, Chang MP, Wisnieski BJ (2005) Mechanistic aspects of the deoxyribonuclease activity of diphtheria toxin. Biochem Biophys Acta 1747(1):121–131PubMedGoogle Scholar
  33. 33.
    Mang YJ, Fletcher R, Yu J, Zhang L (2018) Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis 5(3):194–203CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • E. Babavalian
    • 1
  • M. Zeinoddini
    • 1
    Email author
  • A. R. Saeedinia
    • 1
  • R. Mohammadi
    • 1
  • N. Xodadadi
    • 1
  1. 1.Malek Ashtar University of TechnologyTehranIran

Personalised recommendations